OpenPayd
All
Newsflash
Article
-
Stablecoin payment platform OpenPayd to list on Nasdaq via SPAC at an estimated valuation of approximately $1.145 billion
Svmuu reported that stablecoin payment infrastructure platform OpenPayd has announced a definitive business combination agreement with special purpose acquisition company (SPAC) Titan Acquisition Corp
-
Stablecoin payment platform OpenPayd to list on Nasdaq via SPAC at an estimated valuation of approximately $1.145 billion
Svmuu reported that stablecoin payment infrastructure platform OpenPayd has announced a definitive business combination agreement with special purpose acquisition company (SPAC) Titan Acquisition Corp
- No data
OpenPayd
Svmuu provides news and information related to OpenPayd, as well as real-time data on OpenPayd. We provide in-depth analysis and interpretation of the latest OpenPayd developments, helping investors stay informed about OpenPayd policy updates. Svmuu is your essential tool for keeping up with the latest OpenPayd trends! Here, we’ll join you in keeping a close eye on OpenPayd news and use a clear macro perspective to make sense of the uncertain future of crypto.
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
5
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
6
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
7
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
8
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
9
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
-
10
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
Markets Today
Recommended Reading





